InsightDx Mammostrat test: Phase III data
An analysis of tissue blocks from 4,598 patients treated with Aromasin exemestane and/or tamoxifen in the open-label, international Phase III TEAM trial showed that Mammostrat scores provided significant information on the risk of DRFS after endocrine therapy in estrogen receptor-positive, lymph node-negative patients who were not receiving chemotherapy (n=1,226; p<0.004). Mammostrat scores also provided significant information on the risk of DRFS in all patients who were not receiving chemotherapy, irrespective of nodal status, (n=2,559; p=0.001), as well as in the entire cohort (n=3,837; p<0.0001). Patients in the TEAM trial received Aromasin for 5 years or switched to Aromasin after 2-3 years of treatment with tamoxifen. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...